Chugai diagnostic approved in Japan to match lung cancer patients with Rozlytrek

2 January 2020

The Roche (ROG: SIX) majority-owned subsidiary Chugai (TYO: 4519) has won Japanese approval of a diagnostic that it calls the FoundationOne CDx Cancer Genomic Profile.

This product has been approved as a companion diagnostic of Rozlytrek (entrectinib) for ROS1 fusion-positive non-small cell lung cancer (NSCLC).

The approval allows physicians to identify NSCLC patients who could benefit from the oral tyrosine kinase inhibitor by detecting ROS1 fusion genes. Chugai filed an application in Japan for this additional indication of Rozlytrek for the treatment of ROS1 fusion-positive, locally advanced or metastatic NSCLC on March 15, 2019, and it remains under regulatory review.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK